Cargando…
Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients
BACKGROUND: Malnutrition, weight loss, and muscle wasting (sarcopenia) are common among women with advanced ovarian cancer and have been associated with adverse clinical outcomes and survival. Our objective is to investigate overall survival (OS) related to changes in skeletal muscle (SM) for patien...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782251/ https://www.ncbi.nlm.nih.gov/pubmed/27030813 http://dx.doi.org/10.1002/jcsm.12107 |
_version_ | 1782419916507316224 |
---|---|
author | Rutten, Iris J.G. van Dijk, David P.J. Kruitwagen, Roy F.P.M. Beets‐Tan, Regina G.H. Olde Damink, Steven W.M. van Gorp, Toon |
author_facet | Rutten, Iris J.G. van Dijk, David P.J. Kruitwagen, Roy F.P.M. Beets‐Tan, Regina G.H. Olde Damink, Steven W.M. van Gorp, Toon |
author_sort | Rutten, Iris J.G. |
collection | PubMed |
description | BACKGROUND: Malnutrition, weight loss, and muscle wasting (sarcopenia) are common among women with advanced ovarian cancer and have been associated with adverse clinical outcomes and survival. Our objective is to investigate overall survival (OS) related to changes in skeletal muscle (SM) for patients with advanced ovarian cancer treated with neoadjuvant chemotherapy and interval debulking. METHODS: Ovarian cancer patients (n = 123) treated with neoadjuvant chemotherapy and interval debulking in the area of Maastricht (the Netherlands) between 2000 and 2014 were included retrospectively. Surface areas of SM and adipose tissue were defined on computed tomography at the level of the third lumbar vertebra. Low SM at baseline and SM changes during chemotherapy were compared with Kaplan Meier curves, and Cox‐regression models were applied to test predictors of OS. RESULTS: Median OS for patients who lost SM (n = 83) was 916 ± 99 days, which was significantly different from median OS for patients who maintained or gained SM (n = 40), which was 1431 ± 470 days (P = 0.004). Loss of SM was also a significant predictor of OS in multivariable Cox‐regression analysis (hazard ratio 1.773 (95%CI: 1.018–3.088), P = 0.043). Low baseline SM did not influence survival. CONCLUSIONS: Patients with ovarian cancer have a worse survival when they lose SM during neoadjuvant chemotherapy. Evaluation of low SM at a specific time point is not prognostic for OS. External and prospective validation of these findings is imperative. Nutritional, pharmacological, and/or physical intervention studies are necessary to establish whether SM impairment can be prevented to prolong ovarian cancer survival. |
format | Online Article Text |
id | pubmed-4782251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47822512016-03-30 Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients Rutten, Iris J.G. van Dijk, David P.J. Kruitwagen, Roy F.P.M. Beets‐Tan, Regina G.H. Olde Damink, Steven W.M. van Gorp, Toon J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: Malnutrition, weight loss, and muscle wasting (sarcopenia) are common among women with advanced ovarian cancer and have been associated with adverse clinical outcomes and survival. Our objective is to investigate overall survival (OS) related to changes in skeletal muscle (SM) for patients with advanced ovarian cancer treated with neoadjuvant chemotherapy and interval debulking. METHODS: Ovarian cancer patients (n = 123) treated with neoadjuvant chemotherapy and interval debulking in the area of Maastricht (the Netherlands) between 2000 and 2014 were included retrospectively. Surface areas of SM and adipose tissue were defined on computed tomography at the level of the third lumbar vertebra. Low SM at baseline and SM changes during chemotherapy were compared with Kaplan Meier curves, and Cox‐regression models were applied to test predictors of OS. RESULTS: Median OS for patients who lost SM (n = 83) was 916 ± 99 days, which was significantly different from median OS for patients who maintained or gained SM (n = 40), which was 1431 ± 470 days (P = 0.004). Loss of SM was also a significant predictor of OS in multivariable Cox‐regression analysis (hazard ratio 1.773 (95%CI: 1.018–3.088), P = 0.043). Low baseline SM did not influence survival. CONCLUSIONS: Patients with ovarian cancer have a worse survival when they lose SM during neoadjuvant chemotherapy. Evaluation of low SM at a specific time point is not prognostic for OS. External and prospective validation of these findings is imperative. Nutritional, pharmacological, and/or physical intervention studies are necessary to establish whether SM impairment can be prevented to prolong ovarian cancer survival. John Wiley and Sons Inc. 2016-03-07 2016-09 /pmc/articles/PMC4782251/ /pubmed/27030813 http://dx.doi.org/10.1002/jcsm.12107 Text en © 2016 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the Creative Commons Attribution‐NoDerivs (http://creativecommons.org/licenses/by-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made. |
spellingShingle | Original Articles Rutten, Iris J.G. van Dijk, David P.J. Kruitwagen, Roy F.P.M. Beets‐Tan, Regina G.H. Olde Damink, Steven W.M. van Gorp, Toon Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients |
title | Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients |
title_full | Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients |
title_fullStr | Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients |
title_full_unstemmed | Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients |
title_short | Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients |
title_sort | loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782251/ https://www.ncbi.nlm.nih.gov/pubmed/27030813 http://dx.doi.org/10.1002/jcsm.12107 |
work_keys_str_mv | AT ruttenirisjg lossofskeletalmuscleduringneoadjuvantchemotherapyisrelatedtodecreasedsurvivalinovariancancerpatients AT vandijkdavidpj lossofskeletalmuscleduringneoadjuvantchemotherapyisrelatedtodecreasedsurvivalinovariancancerpatients AT kruitwagenroyfpm lossofskeletalmuscleduringneoadjuvantchemotherapyisrelatedtodecreasedsurvivalinovariancancerpatients AT beetstanreginagh lossofskeletalmuscleduringneoadjuvantchemotherapyisrelatedtodecreasedsurvivalinovariancancerpatients AT oldedaminkstevenwm lossofskeletalmuscleduringneoadjuvantchemotherapyisrelatedtodecreasedsurvivalinovariancancerpatients AT vangorptoon lossofskeletalmuscleduringneoadjuvantchemotherapyisrelatedtodecreasedsurvivalinovariancancerpatients |